deltatrials
Completed PHASE1/PHASE2 NCT00003102

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer

Phase I/II Study of 131I-Labeled Chimeric Antibody G250 (131I-cG250) in Patients With Advanced Renal Carcinoma

Sponsor: Ludwig Institute for Cancer Research

Conditions Kidney Cancer
Interventions Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)
Updated 9 times since 2017 Last updated: Oct 2, 2023 Started: Nov 17, 1998 Primary completion: Apr 19, 2000 Completion: May 27, 2003

This PHASE1/PHASE2 trial investigates Kidney Cancer and is currently completed. Ludwig Institute for Cancer Research leads this study, which shows 9 recorded versions since 1998 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Nov 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Nov 2022 — Nov 2023 [monthly]

    Completed PHASE1_PHASE2

  5. Feb 2022 — Nov 2022 [monthly]

    Completed PHASE1_PHASE2

▶ Show 4 earlier versions

  1. Jan 2021 — Feb 2022 [monthly]

    Completed PHASE1_PHASE2

  2. Apr 2020 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  3. Jun 2018 — Apr 2020 [monthly]

    Completed PHASE1_PHASE2

  4. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Nov 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ludwig Institute for Cancer Research
  • National Cancer Institute (NCI)
Data source: Ludwig Institute for Cancer Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States